Key result
Ginsenoside Rg2 pretreatment attenuates Trastuzumab-induced LV dysfunction and cardiomyocyte apoptosis in preclinical models.
Why the study?
Trastuzumab has significant cardiotoxicity, and this study investigated whether ginsenoside Rg2 attenuates trastuzumab-induced cardiotoxicity.
Does Ginsenoside Rg2 prevent Trastuzumab-induced cardiotoxicity in preclinical models?
Does Ginsenoside Rg2 prevent Trastuzumab-induced cardiotoxicity in preclinical models?
Ginsenoside Rg2 attenuates trastuzumab-induced cardiotoxicity by downregulating proapoptotic proteins, suggesting a potential therapeutic role in preventing cardio-oncologic complications.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Ginsenoside Rg2 in trastuzumab cardiotoxicity; prospective human trials needed before any clinical consideration.
AIM: Trastuzumab (TZM) is a monoclonal antibody drug for HER2-positive breast cancer by targeting epidermal growth factor 2, but it has significant cardiotoxicity. Ginsenoside Rg2 has shown a variety of biological activities. This study was aimed at investigating whether Rg2 attenuates TZM-induced cardiotoxicity. METHODS: A model of TZM-induced cardiotoxicity was established in Wistar rats, and the rats were pretreated with Rg2. After echocardiography analysis, the rats were killed and the hearts were dissected for RNAseq analysis. Primary human cardiomyocytes (HCMs) were treated with TZM with or without pretreatment with Rg2 and then subjected to a colony formation assay, flow cytometry analysis, and Western blot analysis for the detection of caspase-3, caspase-9, and BAX. RESULTS: TZM induced LV dysfunction in rats, but Rg2 could attenuate TZM-induced LV dysfunction. The mRNA levels of caspase-3, caspase-9, and BAX were significantly higher in TZM-treated rats. The colony formation ability of HCMs was significantly lower in TZM-treated cells but was recovered after pretreatment with Rg2. The apoptosis rate of HCMs was significantly higher in TZM-treated cells but was significantly lower after pretreatment with Rg2. Moreover, protein levels of caspase-3, caspase-9, and BAX were significantly higher in TZM-treated cells but were significantly lower after pretreatment with Rg2. CONCLUSION: Ginsenoside Rg2 inhibited TZM-induced cardiotoxicity, and the mechanism may be related to the downregulation of the expression of proapoptotic proteins caspase-3, caspase-9, and BAX and the inhibition of TZM-induced apoptosis in cardiomyocytes. Ginsenoside Rg2 has a potential to be applied in patients with breast cancer to prevent TZM-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2022) studied Trastuzumab-induced cardiotoxicity. Ginsenoside Rg2 vs. Trastuzumab alone was evaluated on LV dysfunction and apoptosis. Pretreatment with Ginsenoside Rg2 attenuated Trastuzumab-induced left ventricular dysfunction in rats and reduced apoptosis in human cardiomyocytes.
Synapse has enriched 10 related papers. Consider them for comparative context: